AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00203424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib + Bevacizumab
Description: Erlotinib every day for 24 weeks and Bevacizumab every 3 weeks for a total of 8 doses
Study NCT04182243 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of job satisfaction in emergency health care providers by questionnaire
Study NCT01010971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclesonide HFA 160 μg
Description: Ciclesonide HFA Nasal Aerosol 160 μg once daily
Study NCT01010971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclesonide HFA 80 μg
Description: Ciclesonide HFA Nasal Aerosol 80 μg once daily
Study NCT01010971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo HFA Nasal Aerosol once daily
Study NCT01011543 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic techniques in pulmonary tuberculosis
Description: Two different methods to obtain a diagnosis of pulmonary tuberculosis in patients with negative classic sputum samples are compared.
Study NCT03017768 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Multimodal stimulation probe
Description: The multimodal esophageal probe allows to perform 4 types of stimulations in the esophagus (thermal, mechanical, electrical and chemical stimulation). These 4 modalities will be evaluated to assess esophageal sensitivity.
Study NCT03937505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IS-001
Description: intravenous injection of IS-001 investigational drug
Study NCT03937505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No treatment
Description: no drug injection
Study NCT02721381 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ImPACT Online
Description: ImPACT Online is an interactive, web-based telehealth intervention that teaches parents to promote their child's social-communication skills during play and daily routines. The intervention content was adapted from Project ImPACT, a manualized parent training curriculum that uses a blend of developmental and naturalistic behavioral intervention techniques, including following the child's lead, imitating the child, using heightened animation, using simplified language around the child's focus of attention, environmental arrangement strategies, prompting, and natural reinforcement during child-directed activities. There is strong empirical support for the intervention techniques for increasing social communication in children, increasing parent fidelity, and child language skills.
Study NCT04727385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double Crosslink Microgel
Description: DXM hydrogel is a pH responsive Double Cross-Linked microgel based on single internally cross-linked microspheres (comprising a methacrylic acid-methyl methacrylate-ethylene glycol dimethacrylate copolymer)~The DXM gel is injected into the intervertebral disc (IVD) space via a standardised procedure similar to the routinely-performed Discography procedure. The disc approach described in the discography procedure has been reported to allow the injection of a solution in the centre of the disc. The injection of the gel takes about 2 min.
Study NCT01809444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone+placebo of Doxycycline
Description: Prednisone: 50 mg/d for 14 day, tailed by 40 mg/d for 14 day, 30 mg/d for 28 day, 20 mg/d for 28 day, 15 mg/d for 14 day, 10 mg/d for 14 day, in total 16 weeks; Placebo of doxycycline: administered for 16 weeks
Study NCT03625102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antroquinonol
Description: Antroquinonol will be provided as a capsule-shaped which contain 50 mg Antroquinonol.
Study NCT03272451 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: culprit vessel intervention
Description: ECG guided immediate culprit vessel intervention using a single transradial guiding catheter such as MAC or JL 3.5
Study NCT03625102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects
Study NCT03625102 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects
Study NCT01789307 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: corn syrup solids
Description: oral ingestion 50 grams, 2 doses
Study NCT01789307 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sucrose
Description: oral ingestion 50 grams, 2 doses
Study NCT01432743 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NavX Fusion
Description: Using NavX Fusion to guide catheter ablation
Study NCT01432743 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cartomerge
Description: Guidance of catheter ablation using Cartomerge guidance
Study NCT06283654 — intervention group
Intervention type: DEVICE
Intervention: 1-lead ECG
Description: patient were handed out a 1 lead ECG device, they were free to use it anyway they wanted, even not at all
Study NCT02078141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-deoxyglucose (FDG)
Description: 18F-deoxyglucose (FDG) One injection of 3.5 MBq/kg of 18FDG with a minimum of 220 MBq and a maximum of 400 MBq
Study NCT03131375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Group A and B: Anesthesia induction drugs:propofol, fentanyl, rocuronium . After induction of anesthesia: Group A receives a 50 ml NS infusion containing 1 mcg kg-1 Dexmedetomidine drug Group A and B: Atropine as an antisialagogue, dexamethasone, ondasetrone for the prevention of postoperative nausea and vomiting. Anesthesia maintainance: propofol, remifentanil and oxygen in air. End of surgery, the infusion of propofol and remifentanil stop and sugammadex for reversal of neuromuscular block is given. Postoperative analgesia by nalbuphine 0.2 mg kg-1 given before the end of surgery in Group B, and 0.16 mg kg-1 in Group A. Monitoring: ECG, NIBP, ETCO2, SpO2, Bispectral index , Train of four ratio.
Study NCT03131375 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Group A and B: Anesthesia induction drugs:propofol, fentanyl, rocuronium . After induction of anesthesia: Group B receives a volume matched Normal saline infusion. Group A and B: Atropine as an antisialagogue, dexamethasone, ondasetrone for the prevention of postoperative nausea and vomiting. Anesthesia maintainance: propofol, remifentanil and oxygen in air. End of surgery, the infusion of propofol and remifentanil stop and sugammadex for reversal of neuromuscular block is given. Postoperative analgesia by nalbuphine 0.2 mg kg-1 given before the end of surgery in Group B. Monitoring: ECG, NIBP, ETCO2, SpO2, Bispectral index, Train of four ratio.
Study NCT03131375 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bispectral index
Description: Group A and B: Monitoring depth of anesthesia by BIS device and adjusting propofol infusion according to measurements, aiming to BIS values: 40-60
Study NCT03131375 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Bispectral index
Description: Group A and B: Monitoring depth of anesthesia by BIS device and adjusting propofol infusion according to measurements, aiming to BIS values: 40-60
Study NCT02329509 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: two stage palate surgical repair
Description: two stage palate surgical repair with a hard palate closure at 3 to 4 years old
Study NCT03131375 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Train of four ratio
Description: Group A and B: Monitoring recovery of neuromuscular function with TOF-Watch device, to ensure TOFR equals or greater than 90% at the end of the procedure
Study NCT03272451 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional approach
Description: single diagnostic catheter for complete coronary angiography and guiding catheter selection for PCI
Study NCT01020058 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mesh repair for primary inguinal hernia
Description: Open Lichtenstein repair in local anesthesia using a polypropylene mesh compared to totally extra-peritoneal laparoscopic repair using a polypropylene mesh
Study NCT01809444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline+placebo of Prednisone
Description: Doxycycline: 50 mg PO per day for 12 weeks, and placebo for another 4 weeks; Placebo of prednisone: administered for 16 weeks.
Study NCT02077114 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine consisting of a peptide derived from the protein IDO
Description: All patients will receive seven vaccines containing IDOlong
Study NCT03131375 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Train of four ratio
Description: Group A and B: Monitoring recovery of neuromuscular function with TOF-Watch device, to ensure TOFR equals or greater than 90% at the end of the procedure
Study NCT04408326 — intervention group
Intervention type: DRUG
Intervention: Angiotensin II
Description: Exogenous angiotensin II acts on angiotensin II type 1 receptor and raise blood pressure by vasoconstriction, salt and water retention, and stimulation of aldosterone hormone
Study NCT04408326 — intervention group
Intervention type: DRUG
Intervention: Interleukin-1 receptor antagonist
Description: Interleukin-1 receptor antagonist is an immunomodulating drug aiming to mitigate cytokine storm in COVID-19 patients
Study NCT01224600 — intervention group
Intervention type: OTHER
Intervention: patients with newly diagnosed PAD (<1year)
Description: patients with newly diagnosed PAD (\<1year) symptomatic or asymptomatic, without any history of previous coronary nor cerebrovascular event, and with no previous investigation of the aorta and cervical arteries were eligible
Study NCT02329509 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One stage Palate Surgical repair
Description: One stage palate repair at the age of 9 to 24 months old
Study NCT04571853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PNE-explained group
Description: There are 9 fact sheets overall. And each fact sheet incorporates two pages relating to one main concept. The first of two pages introduces the concept, and the second one quotes important ideas that emerge from the main concept. The 9 main concepts and consequent ideas presented in the fact sheets are based on current scientific research in pain science and have been selected and structured specifically for PNE education for chronic pain patients. The fact sheets have been fully developed and designed by Pain Revolution, a pain educator network founded by Professor Lorimer Moseley, group leader in Body in Mind Research Group from University of South Australia.
Study NCT04571853 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PNE-read group
Description: The PNE-read group will receive the fact sheets via email along with instructions regarding the content and the procedure to read the content. Instructions will suggest to read only two fact sheets per day during 4,5 days. It will be suggested to take 30 minutes at least for each fact sheet.
Study NCT04571853 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU group
Description: Participants allocated to this group will maintain treatment as usual (TAU) and will follow the recommendations by their usual health professiona
Study NCT03493477 — intervention group
Intervention type: OTHER
Intervention: exposure will be abnormal skeletal jaw relations
Description: Class II skeletal jaw relation or class III skeletal jaw relation based on lateral cephalometric radiograph
Study NCT02640482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493/ABT-530
Description: Tablet; ABT-493 coformulated with ABT-530
Study NCT02640482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABT-493/ABT-530
Description: tablet
Study NCT01428388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal injection of bevacizumab
Description: 1.25 mg per dose, delivered monthly by intravitreal injection for six months
Study NCT01428388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal injection of ranibizumab (0.5 mg per dose)
Description: 0.5 mg per dose, delivered monthly by intravitreal injection for six months
Study NCT00777790 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Description: 0.5 mL, Intramuscular
Study NCT00752063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib with Capecitabine and Oxaliplatin
Description: Regimen 1: Oxaliplatin 85 mg/m2 (50 mg per vial) administered intravenously on day 1 of each cycle Regimen 2: Capecitabine 1700 mg/m2 p.o. (850 mg/m2 BD) day 1 to 7 Regimen 3: Sorafenib 400 mg (200 mg/tablet) orally BD day 1 to 14
Study NCT03975465 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expiratory Muscle Strength Training
Description: 8 weeks of EMST at 75% maximum expiratory pressure (MEP)
Study NCT03975465 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pharyngeal Muscle Strengthening Exercises
Description: 8 weeks of exercises designed to increase pharyngeal muscle strength for swallowing
Study NCT04064190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vactosertib(TEW-7197)/ Durvalumab
Description: Vactosertib (PO) in combination with Durvalumab (IV) every 4 weeks
Study NCT03287089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin 100 MG
Description: Patients will receive nitrofurantoin 100mg twice daily by mouth for 5 days
Study NCT03287089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Matching placebo
Study NCT04468100 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tigerase®
Description: 2.5 mL (2.5 mg) dornase alfa nebulized once daily for 168 (+/-7) days
Study NCT04785872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: NEUMAN SYSTEMS MODEL BASED NURSING APPROACH
Study NCT00681343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Induction
Study NCT00681343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath-1H
Description: Induction
Study NCT00681343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclizumab
Description: Induction
Study NCT01506388 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: foley catheter
Description: foley 14 catheter intracervical plus vaginal IMN 40 mg evry 6 hours
Study NCT01506388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: misoprostol 50 Ug , vaginally every 4-6 hours
Study NCT01506388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal IMN
Description: IMN vaginal 40 mg every 4-6 hours
Study NCT00613808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric Oxide 200ppm Group B
Description: 200 ppm, 8hrs / day for 6 weeks
Study NCT00089804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abetimus sodium (LJP 394) and/or placebo solution
Description: 300 mg (50 mg/mL)abetimus sodium (three 2 mL vials of of abetimus sodium plus six 2 mL vials of normal saline) administered i.v. (in the vien) weekly for 52 weeks
Study NCT00089804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abetimus sodium (LJP 394)
Description: 900 mg (50 mg/mL) abetimus sodium (nine 2 mL vials) administered i.v. (in the vien) weekly for 52 weeks.
Study NCT00089804 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate-buffered saline
Description: A volume of 18 mL (nine 2 mL vials of normal saline) of identically appearing placebo (phosphate-buffered saline) administered i.v. (in the vien) weekly for 52 weeks
Study NCT04468100 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pulmozyme®
Description: 2.5 mL (2.5 mg) dornase alfa nebulized once daily for 168 (+/-7) days
Study NCT04783402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-OTCAT program
Description: The e-OTCAT program consists of a combination of cognitive training in terms of attention, memory and processing speed; and adaptive training based on metacognition and cognitive-behavioral strategies (psycho-education, relaxation techniques training, stress management, energy conservation techniques, time management, etc.).~This program also includes homework exercises consisting of a handbook of paper-and-pencil exercises, a cognitive training mobile app, and the practice of strategies seen in adaptive training sessions.
Study NCT04783402 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Educational handbook and standard care
Description: At the beginning of chemotherapy, the participants will receive an educational handbook containing information about most frequent side-effects of cancer and cancer treatments, plus standard care.
Study NCT00268450 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Before surgery: given as a 15mg/kg IV over 90 minutes every 21 days for 4 cycles~After surgery: given as a 15mg/kg IV over 90 minutes every 21 days for 3 cycles
Study NCT03666494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Hydrochloride
Description: As part of anesthetic induction, the addition of ketamine hydrochloride 0.5mg/kg.
Study NCT03666494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: As part of the patient's anesthetic induction, they will receive propofol.
Study NCT03954080 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraspinal-optimal stim therapy
Description: During the trial, percutaneous lead(s) will be implanted, following standard clinical practices, in the posterior epidural space with the final lead position located in the optimal area to provide pain relief by stimulating neural tissue in order to create paresthesia(s) only on the painful dermatome(s). During Intraspinal-Optimal Stim, a set of electrodes in the stimulation lead(s) will deliver a charge-balanced, pulsed electrical signal with stimulation parameters (frequency, pulse width, and amplitude) within the FDA approved specifications of the commercially available external neurostimulator. These will be adjusted to produce paresthesia coverage of the painful area. Patients that will report equal or greater than 50% reduction in pain, relative to baseline pain, may undergo permanent implantation of a commercially available neurostimulator (INS). This will require a surgical intervention to implant stimulation leads, INS and anchoring hardware followed by therapy programming.
Study NCT01035489 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT in heart failure; Right ventricular apex v.s. high posterior septum
Description: RV lead is randomized to either apex or high posterior septum
Study NCT04385459 — intervention group
Intervention type: OTHER
Intervention: Coronary artery disease
Description: Exposure
Study NCT00596752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprostadil
Description: * Active Substance: Prostaglandin E1~* Pharmaceutical Form: solution for infusion~* Concentration: 40 μg b.d.~* Route of Administration: intravenous infusion
Study NCT00596752 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Active Substance: Lactose~* Pharmaceutical Form: solution for infusion~* Concentration: 40 μg b.d.~* Route of Administration: intravenous infusion
Study NCT02745834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait analysis
Description: Gait will be analysed while participants will walk on a treadmill at different self selected speeds, using the OPTOGait system. Spatiotemporal measures are collected without the use of any markers.
Study NCT03206801 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney transplant biopsy
Description: Elevated urine CXCL10 will trigger a study biopsy in patients randomized to the intervention arm. Subclinical rejection will be treated per protocol.
Study NCT02843672 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Triple Weil´s Osteotomy
Description: A 10mm longitudinal incision is made with a No.15 blade in the second intermetatarsal space immediately behind the dorsal interdigital fold, parallel to the extensor tendon. An intra-articular osteotomy in the metatarsal head is performed angled 45º relative to the long axis of the metatarsal and in a dorsal-distal to proximal-plantar direction. A second osteotomy is performed perpendicular to the metatarsal shaft,.The osteotomy is fastened with a 2.0mm snap-off screw.~Once all the osteotomies are completed, the incisions are closed with a 2/0 monofilament suture.
Study NCT02843672 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal metatarsal minimally invasive osteotomy
Description: A 5mm longitudinal incision is made with a MIS blade No.64 in the intermetatarsal space immediately behind the dorsal interdigital fold, parallel to the extensor tendon. Under fluoroscopy vision, an extra-articular osteotomy in the metatarsal neck is performed angled 45º relative to the long axis of the metatarsal and in a dorsal-distal to proximal-plantar direction. The osteotomies scheduled preoperatively are performed, repeating the same procedure for each ray needing an osteotomy. Once all are completed, the incisions are closed with a 4/0 monofilament suture.